Perivascular Epithelioid Cell Tumors (PEComa) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Perivascular epithelioid cell tumors (PEComa) are a family of rare mesenchymal tumors composed of histologically and immunohistochemically distinctive perivascular epithelioid cells. These tumors include renal angiomyolipoma; lymphangioleiomyomatosis; clear cell sugar tumor of the lung; and similar tumors occurring in the retroperitoneum, kidney, uterus, and pancreas and in a variety of other visceral and soft-tissue sites. PEComas of the kidney includes various histologic subtypes of angiomyolipomas such as the classic angiomyolipoma, epithelioid angiomyolipoma, oncocytomalike angiomyolipoma, and lymphangiomyomatosis of the renal sinus. PEComas are related to the tuberous sclerosis complex (TSC) and have the characteristic genetic alterations of TSC including the deletions of the short arm of chromosome 16p (TSC2 gene). PEComas are histologically characterized by their perivascular location, usually epithelioid or occasionally spindle cell morphology, and coexpression of human melanoma black (HMB)-45 and smooth-muscle markers.

·       PEComas-NOS arises at diverse visceral and soft tissue sites. Perivascular epithelioid cell tumors of the gastrointestinal tract (GI PEComas-NOS) take a proportion of about 20% to 25% of PEComas-NOS. The overall incidence of Perivascular epithelioid cell tumors (PEComa) in the USA is 0.5 to 1.3 per million population.

Thelansis’s “Perivascular Epithelioid Cell Tumors (PEComa) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Perivascular Epithelioid Cell Tumors (PEComa) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Perivascular Epithelioid Cell Tumors (PEComa) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Perivascular Epithelioid Cell Tumors (PEComa) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Perivascular Epithelioid Cell Tumors (PEComa) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Comments

Popular posts from this blog

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034